AVP-786 disappoints in treatment of agitation-associated dementia due to Alzheimer's in initial findings

Written By : Aditi

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-02-19 22:15 GMT | Update On 2024-02-19 22:16 GMT

Agitation associated with dementia caused by Alzheimer's disease is a prevalent neuropsychiatric symptom affecting approximately half of all Alzheimer's dementia patients. This condition substantially impacts the quality of life for patients, their families, and caregivers. Agitation associated with dementia caused by Alzheimer's disease encompasses various behaviors such as pacing, gesturing, profanity, shouting, shoving, and hitting. Additionally, this symptom is a consistent predictor of nursing home admission.

Results from a phase 3 study evaluated the efficacy and safety of AVP-786 for treating agitation associated with dementia due to Alzheimer's disease.

AVP-786 combines deudextromethorphan hydrobromide (d6-DM) and quinidine sulfate (Q), a CYP2D6 inhibitor. Deuteration reduces susceptibility to cytochrome P450 (CYP2D6) enzyme metabolism, increasing bioavailability.

The study included 600+ patients aged 50+ with dementia due to Alzheimer's disease and moderate to severe agitation. In a randomised, double-blind, parallel-design trial, participants received AVP-786 or a placebo twice daily for 12 weeks.

AVP-786 treatment did not significantly improve agitation in dementia patients with Alzheimer's disease, as shown by the change in the Cohen-Mansfield Agitation Inventory total score (primary endpoint). Falls were reported more frequently in the AVP-786 groups (8.6% for high dose, 9.1% for low dose, 2.8% for placebo)

Dr. John Kraus, executive vice president and chief medical officer at Otsuka, mentioned that the complete study findings still need to be released. Further, prespecified and exploratory analyses will be conducted to determine AVP-786's full potential. Otsuka intends to submit the trial results for publication at a later date. They thanked the study participants, their caregivers, and the investigators who participated in this trial.

Otsuka Pharmaceutical Co., Ltd. is a global healthcare corporation dedicated to developing innovative products for better health worldwide. The company focuses on pharmaceutical products to address unmet medical needs and nutraceutical products to maintain everyday health. Otsuka is a leader in mental, renal, and cardiovascular health and also has research programs in oncology and under-addressed diseases like tuberculosis.

References:

Otsuka announces phase 3 topline results of AVP-786 in the treatment of agitation associated with dementia due to Alzheimer's disease. News release. Otsuka Pharmaceutical. February 12, 2024. Accessed February 13, 2024. https://www.businesswire.com/news/home/20240212652874/en/Otsuka-Announces-Phase-3-Topline-Results-of-AVP-786-in-the-Treatment-of-Agitation-Associated-With-Dementia-Due-to-Alzheimer%E2%80%99s-Disease.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Aditi

Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

AVP-786 disappoints in treatment of agitation-associated dementia due to Alzheimer's in initial findings

Similar News

Heart-healthy habits also prevent cancer, Alzheimer’s, COPD, other diseases, Emory study finds

COVID-19 Infection May Accelerate Vascular Aging and Raise Heart Disease Risk: Study Suggests

Cochrane Review Raises Concerns Over Off-Label Use of Ketamine for Chronic Pain

Antiseizure Medications Show No Significant Impact on Epilepsy Risk After Brain Abscess: JAMA

Could Your Sensitivity Be Affecting Your Mental Health? Study Finds Out

New 2025 Hypertension Guidelines Released with Stronger Focus on Brain Health and Early Intervention

Hospitalisation in COPD Patients Linked to Sharp Rise in Cardiovascular Events and Mortality: Study

Cardiometabolic Diseases Significantly Accelerate Onset and Worsening of Neuropsychiatric Disorders: Study Finds